DOM FIGURE 5 Gene expression of Prkaa1 and Prkaa2 is increased by substrate challenge in hepatocytes from vehicle treated mice ex vivo and by chronic treatment with AZD1656 (3mg/kg) for 8 wk.
Datasets usually provide raw data for analysis. This raw data often comes in spreadsheet form, but can be any collection of data, on which analysis can be performed.
mRNA levels for Prkaa1 (AMPK-alpha1) and Prkaa2 (AMPK-alpha2) were determined in the experiments described in Fig. 4 in hepatocytes isolated from mice treated for 8-weeks with vehicle or AZD1656 (1 or 3 mg/kg) and then challenged for 4h with the substrates indicated as in Fig. 4I-P. A-B. mRNA levels for Prkaa1 and Prkaa2 normalized to hepatocytes from vehicle treated mice in basal conditions (5mM glucose). C-D. mRNA levels of Prkaa1 and Prkaa2 normalized to the respective controls at 5mM glucose. Means ± SEM, n=4, *P< 0.05 vs respective control (5G); # P < 0.05 vs respective untreated (0 mg/kg).
MICA: Exploring a new perspective on the mechanism of action of Glucokinase Activators in liver, a preclinical study
Medical Research CouncilFind out more...